On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Show notes
1. Biosimilars Check-In: Application Acceptances, European Approvals, New Partnerships
2. Overcoming Economic, Noneconomic Barriers to Biosimilar Adoption in Oncology
3. EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions
4. New Data Show Safety of Ado-Trastuzumab, Trastuzumab Biosimilars in HER2+ Cancers
5. ASCO Posters Reflect on Reimbursement Trends, Combination Therapies Involving Biosimilars
6. ASCO 2024 Posters Showcase Positive Data on Denosumab, Pegfilgrastim Biosimilars
7. Authors Spotlight Long-Term Solutions to Ensure Biosimilar Market Sustainability
8. Part 2: Unlocking the Potential of Biosimilars to Improve Health Equity
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Trastuzumab-dkst Shows Promising Results in Real-World Setting for HER2+ Breast Cancer
July 9th 2024A Brazilian real-world study found trastuzumab-dkst to be an effective and safe adjuvant therapy for HER2-positive (HER2+) breast cancer, with clinical outcomes comparable to reference trastuzumab.